Derek DiRocco - 24 May 2024 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Reporting relationship: Director
Issuer ticker: HOWL
Reported as of: 24 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 May 2024, 19:52:50 UTC
Prior SEC filing: 23 May 2024
Next SEC filing: 24 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Owen, Attorney-in-fact

Key filing fact

Derek DiRocco filed Form 4 for Werewolf Therapeutics, Inc. (HOWL) on 24 May 2024.

Key facts

This page summarizes Derek DiRocco's Form 4 filing for Werewolf Therapeutics, Inc. (HOWL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 May 2024, 19:52.

Change

Previous filing in this sequence was filed on 23 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HOWL transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 24 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $4.88
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.